B.Riley Financial analyst Yuan Zhi maintains $Perspective Therapeutics (CATX.US)$ with a buy rating, and adjusts the target price from $17 to $9.
According to TipRanks data, the analyst has a success rate of 32.9% and a total average return of 14.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Perspective Therapeutics (CATX.US)$'s main analysts recently are as follows:
Recent data released by Perspective Therapeutics for VMT-alpha-NET did not meet the expected overall response rate (ORR), as anticipated from established benchmarks from its competitors. Despite this, there remains potential for improved responses with higher dosages, although further data might not be available until late-2025, contingent upon FDA's decision on Cohort 3. Moreover, preliminary findings for VMT01 in treating melanoma have exhibited complications with kidney accumulation, which restricts higher dose applications. This issue may persistently impact the stock's performance until more conclusive results from additional combination studies are obtained.
Initial data from Cohort 1 and Cohort 2 of VMT-a-NET's phase I/IIa study demonstrates encouraging signals, yet also underscores the necessity for dose optimization patience. There is a recognized path to potential commercial success for Perspective's lead-specific chelator across its pipeline and platform.
The recent sharp decline in Perspective Therapeutics' stock is seen as an exaggerated reaction to preliminary data from the dose escalation phase of the VMT-alpha-NET program. The findings revealed clinical activity consistent with dose intensity and confirmed a favorable safety profile, which supports continued dose escalation. The stock currently trades near cash levels, presenting a potential buying opportunity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
